Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €28.29 EUR
Change Today +0.185 / 0.66%
Volume 0.0
ZEGA On Other Exchanges
New York
As of 10:48 AM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

astrazeneca plc-spons adr (ZEGA) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/23/15 - €34.15
52 Week Low
08/24/15 - €25.92
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

astrazeneca plc-spons adr (ZEGA) Details

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. Its products include Crestor for dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL to control hypertension, and heart failure and angina; Onglyza for diabetes mellitus; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders; Pulmicort Turbuhaler/Pulmicort Flexhaler for treating asthma; Symbicort for maintenance treatment of asthma and chronic obstructive pulmonary disease; Nexium to treat acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients. As of December 31, 2014, it had 133 pipeline projects. The company markets its products through distributors and local representative offices. It also engages in the insurance and reinsurance underwriting business. The company has collaboration agreements with Celgene Corporation, Immunocore Limited, Kyowa Hakko Kirin Co., Ltd., Advaxis Inc., Pharmacyclics Inc., The University of Manchester, and Janssen Research & Development, LLC., as well as a strategic collaboration with Isis Pharmaceuticals, Inc. to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases. It also has a license from Heptares Therapeutics Ltd. to develop, manufacture, and commercialize the adenosine A2A receptor antagonist, HTL-1071. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.

57,500 Employees
Last Reported Date: 03/10/15
Founded in 1992

astrazeneca plc-spons adr (ZEGA) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: 3.1M GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 1.7M GBP
Compensation as of Fiscal Year 2014.

astrazeneca plc-spons adr (ZEGA) Key Developments

AstraZeneca PLC Presents at Australia Biotech Invest 2015, Oct-07-2015 09:30 AM

AstraZeneca PLC Presents at Australia Biotech Invest 2015, Oct-07-2015 09:30 AM. Venue: Crown Conference Centre, Crown Promenade Hotel, Melbourne, Victoria, Australia. Speakers: Ajay Gautam, Executive Director, IMED Scientific Partnering & Alliances.

AstraZeneca Announces Availability of New Dose of Brilinta in US Pharmacies

AstraZeneca announced that BRILINTA® (ticagrelor) 60-mg tablets are now available in US pharmacies. On September 3, 2015, the US Food and Drug Administration (FDA) approved a new 60-mg dosage strength for BRILINTA to be used in patients with a history of heart attack beyond the first year. BRILINTA is approved to reduce the rate of cardiovascular (CV) death, myocardial infarction ([MI], also known as heart attack) and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, BRILINTA is superior to clopidogrel. BRILINTA is the first and only FDA approved oral antiplatelet to demonstrate superior reductions in CV death versus clopidogrel at 12 months. The dosing of BRILINTA in the management of ACS is 90 mg twice daily during the first year after an ACS event. After one year, patients with a history of heart attack can now be treated with 60 mg twice daily. BRILINTA must be used with a daily maintenance dose of aspirin of 75-100mg. AstraZeneca is committed to supporting patient access to BRILINTA and connecting patients with the information and support they need. For patients who have been prescribed BRILINTA, AstraZeneca offers the BRILINTA Patient Support Service (BPSS) tool that provides resources and support to help patients and caregivers from hospital discharge throughout the ACS treatment journey. To help loved ones, the program offers important patient education and coaching in addition to savings offers, refill reminders, personal pharmacy locator, co-pay calculator, and coverage verification and information.

AstraZeneca PLC Presents at Leerink Partners Immuno-Oncology Roundtable, Oct-01-2015 03:40 PM

AstraZeneca PLC Presents at Leerink Partners Immuno-Oncology Roundtable, Oct-01-2015 03:40 PM. Venue: Le Parker Meridien Hotel, New York, New York, United States. Speakers: Robert Iannone, SVP, Head of Immuno-oncology, Global Medicines Development.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZEGA:GR €28.29 EUR +0.185

ZEGA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $149.90 USD +0.42
AbbVie Inc $55.64 USD -0.40
BASF SE €72.98 EUR +0.72
Celgene Corp $117.38 USD -0.59
Eli Lilly & Co $86.14 USD +2.37
View Industry Companies

Industry Analysis


Industry Average

Valuation ZEGA Industry Range
Price/Earnings 68.5x
Price/Sales 3.2x
Price/Book 4.4x
Price/Cash Flow 68.4x
TEV/Sales 3.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC-SPONS ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at